الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is known to be the most common enzymopathy in the world and affects ” " ~ " ”7% of the global population while 4.3% of newborn in Egypt are affected with the disease with male to female ratio 3.2:1
After the emergence of COVID-19 pandemic, effective drugs against COVID-19 are searched and intensive research on possible repurposing of antiviral agents are performed.
Due to that Hydroxychloroquine (HCQ) has a broad-spectrum antiviral effect against SARS coronavirus and lately since Chloroquine (CQ) and HCQ have shown in vitro anti- COVID-19 activities the potential effect of CQ/HCQ to treat and/or prevent COVID-19 infection has caused global attention., G6PDD is one of the most involved hematological disorders in COVID-19 infection and above all, in patients taking HCQ.
There are studies conducted in Egypt like Arnaout et al, and Hafez and coworker to identify the most prevalent G6PD mutation at Cairo and El-Mansoura cities. And there were differences between their results, Therefore, different molecular studies should be per¬formed covering the various regions of Egypt due to the complexity and the different ethnic origins of the Egyptian population.
So, in that study in the light of the importance of the relation between G6PD deficiency and the COVID-19 management. This study was conducted to identify the prevalence of The Mediterranean variant 563 (C→T) and G6PD silent 1311(C→T) mutation among the G6PD deficient children in Ismailia city.